Safe Deoxycholic Acid Injection Technique for Submental Fat Reduction
Abstract
Body contouring is gaining popularity in the aesthetic world, as many patients are opting for non-surgical treatments to reduce fat and to improve their appearance. Prior to 2015, patients seeking cosmetic enhancement to reduce submental fat (SMF) typically underwent submental liposuction. Health Canada and the United States Food and Drug Administration approved deoxycholic acid for the reduction of moderate-to-severe SMF in 2015. Deoxycholic acid (BELKYRA™, Allergan, Madison, NJ) is a minimally invasive injectable treatment for the non-surgical reduction of submental adipose tissue. It is a synthetic bile acid that acts on adipocytes by emulsifying fats. Upon injection in the submental fat, it disrupts plasma membranes and ultimately induces adipocyte cell lysis. This is followed by an inflammatory reaction, with a subsequent reduction in fat. The swelling takes up to a week to resolve, and then tissue remodelling takes place over months. In one of the early randomized controlled trials (RCT) comparing deoxycholic acid to placebo, between 64 – 69% of patients (n=360) were highly satisfied with the appearance of their face and chin using the Subject Self-Rating Scale (SSRS score ≥4) after up to 4 treatments compared to 29% in the placebo group (P < 0.001). Deoxycholic acid injection can be a safe and effective addition to a dermatologist’s cosmetic practice, with a high rate of patient satisfaction.
The first portion of this article will address the safety concerns of deoxycholic acid treatment, outlining not only the common adverse effects (AEs) but also highlighting rare side effects that have been reported in case reports and case series. The second portion of the article will review patient selection, anatomic considerations, and injection techniques to achieve a safe outcome.
References
Kirk DS. Deoxycholic acid injection for the reduction of submental fat in adults. AAOMS. 2016;e-53.
Ascher B, Hoffman K, Lippert S, Wollina U, Havliickova. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study. J Eur Acad Dermatol Venerol. 2014;28:1707-15.
Rzany B, Griffiths T, Walker P, Lippert J, McDiarmid J, Havlickova B. Reduction of unwanted subdermal fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study. Br J Dermatol. 2014;170:445-53.
Jones DH, Carruthers J, Joseph JH et al. REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction. Dermatol Surg. 2016;42(1):38-49.
Humphrey M, Sykes J, Kantor J et al. ATX-101 for reduction of submental fat: A phase III randomized controlled trial. Dermatol Surg. 2016;75:4.
Hridharani SM. Early experience in 100 consecutive patients with injection adipocytolysis for neck contouring with ATX-101 (deoxycholic acid). Dermatol Surg. 2017;43(7):950-8.
Shridharani SM. Real-world experience with 100 consecutive patients undergoing neck contouring with ATX-101 (deoxycholic acid): An updated report with a 2-year analysis. Dermatol Surg. 2019;45(10):1285-93.
Grady B, Porphirio F, Rokhsar C. Submental alopecia at deoxycholic acid injection site. Dermatol Surg. 2017;43(8):1105-8.
Souyoul S, Gioe O, Emerson A, Hooper DO. Alopecia after injection of ATX-101 for reduction of submental fat. JAAD Case Reports. 2017;3:250-2.
Wambier CG. Alopeica em barba causada por desoxicolato para tratamento de gordura submentoniana. Surg Cosmet Dermatol. 2017;9(3):259-60.
Sebaratnam DF, Wong XL, Kim L, Cheung K. Alopecia following deoxycholic acid treatment for submental adiposity. JAMA Facial Plast Surg. 2019;21(6):571-2.
Riswold K, Flynn V. A cautionary tale: A vascular event with deoxycholic acid injection. Dermatol Surg. 2018;44(6):887-9.
McKay C, Price C, Pruett L. Vascular injury after deoxycholic acid injection. Dermatol Surg. 2019;45(2):306-9.
Sachdev D, Fabi SG. Deoxycholic acid-induced skin necrosis: Prevention and management. Dermatol Surg. 2018;44(7):1037-9.
Ramirez MR, Marinaro RE, Warthan ML, Burton CS. Permanent cutaneous adverse events after injection with deoxycholic acid. Dermatol Surg. 2019;45(11):1432-4.
BELKYRATM deoxycholic acid injection product monograph, Kythera Biopharmaceuticals, Inc. Accessed [April 10, 2020].